论文部分内容阅读
目的 :观察细胞因子 r IL-2、TNF-α、IFN-γ对抗 CD3 -抗胶质瘤双特异性抗体 (双抗 )的协同作用 ,进一步提高双抗对人脑胶质瘤的治疗作用。 方法 :以人脑胶质瘤细胞株 SHG-4 4为靶细胞 ,健康人或胶质瘤患者的外周血单个核细胞 ( PBMC)为效应细胞 ,以 1 8h3 H-Td R掺入释放法测定细胞毒活性 ,采用单比实验和联合作用等对比分析方法 ,分析各细胞因子 ( r IL-2、TNF-α、IFN-γ)对双抗诱导的细胞毒性作用的影响。 结果 :r IL-2、TNF-α、IFN-γ均可协同提高双抗对人脑胶质瘤的细胞毒作用 ( P<0 .0 5)。来源于恶性胶质瘤患者的效应细胞活性较正常人低 ,r IL-2与双抗可协同增强其活性。结论 :细胞因子 r IL -2、TNF-α、IFN-γ可协同提高双抗对效应细胞的活化 ,充分激活效应细胞 ,增强抗肿瘤免疫能力。
Objective: To observe the synergistic effect of cytokines IL-2, TNF-α and IFN-γ against CD3-anti-glioma dual-specific antibody (double antibody), and further improve the therapeutic effect of dual anti-human glioma. METHODS: Human brain glioma cell line SHG-4 4 was used as target cells. Peripheral blood mononuclear cells (PBMCs) from healthy humans or glioma patients were effector cells and measured by 18h3H-Td R incorporation release method. The cytotoxicity activity was analyzed by single ratio assays and combined assays to analyze the effects of cytokines (r IL-2, TNF-α, and IFN-γ) on cytotoxicity induced by double antibodies. RESULTS: IL-2, TNF-α, and IFN-γ all synergistically enhanced the cytotoxicity of the double-antibody on human gliomas (P<0.05). The effector cells derived from malignant glioma patients have lower activity than normal humans, and rIL-2 and double antibodies can synergistically increase their activity. Conclusion: The cytokines r IL-2, TNF-α, and IFN-γ can synergistically increase the activation of effector cells by double antibodies, fully activate effector cells, and enhance anti-tumor immunity.